Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
Highlights from ICML 2017: The CLL2-BAG study
Inherited and acquired genetic factors involved in the development of CLL
John Gribben et al.
What leads to shorter progression-free survival in CLL patients?
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?